The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)
Condition or disease
Parkinsons Disease With Dementia
Drug: High dose ANAVEX2-73Drug: Mid dose ANAVEX2-73Drug: Placebo oral capsule
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration Period), and a 2-week Safety Follow-Up Period
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia
Actual Study Start Date :
July 9, 2018
Estimated Primary Completion Date :
July 31, 2020
Estimated Study Completion Date :
July 31, 2020
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
50 Years to 85 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of idiopathic Parkinson's disease (PD) consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria.
Diagnosis of probable PD dementia (PDD) according to the Movement Disorder Society Task Force clinical diagnostic criteria.
Montreal Cognitive Assessment (MoCA) score of 13 to 23, inclusive, at Screening.
Male or female and aged ≥ 50 years.
Caregivers and subjects (or legal representative) must understand and have signed approved informed consent.
Caregivers and subjects (or legal representative) must be able to understand study requirements and be willing to follow instructions.
Stable regimen of anti-Parkinson's disease medications (including levodopa, dopamine agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable for at least 4 weeks prior to Baseline.
Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable for a minimum of 8 weeks prior to randomization.
Subjects with history of depression on antidepressant medications will be allowed if depression is controlled and they have been on a stable daily dose of the antidepressant for ≥8 weeks before Baseline.
Women of childbearing potential must use an acceptable method of contraception starting 4 weeks prior to study drug administration and for a minimum of 4 weeks after study completion. Otherwise, women must be postmenopausal (at least one year absence of vaginal bleeding or spotting) as confirmed by FSH greater than or equal to 40 mIU/mL or 40 IU/L or be surgically sterile.
Men with a potentially fertile partner must have had a vasectomy or be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation.
History of any significant neurologic or psychiatric disorder other than PD that can contribute to cognitive impairment.
Any other condition or clinically significant abnormal findings like severe co-morbidities e.g. history of stroke, poor kidney or liver function on the physical or neurological examination, medical and psychiatric history, at screening or at baseline that, in the opinion of the Investigator, would make the subject unsuitable for the study.
Potential symptomatic causes of cognitive impairment including but not limited to
abnormal thyroid function test at screening (TSH)
abnormal B12 level at screening
MRI findings (by history) pointing to a potential symptomatic cause of cognitive dysfunction, including significant vascular changes, or communicating hydrocephalus.
Treatment with memantine or amantadine. If appropriate the drugs can be discontinued for a minimum of 4 weeks prior to randomization.
Use of over the counter (OTC) or prescription medication for sleep on 2 or more occasions per week (less than that is allowed).
History of depression as measured by Beck Depression Inventory score >17 at screening.
Treatment with any other investigational drug or device within 4 weeks prior to screening.
Smoking > 1 pack of cigarettes per day (as assessed for the 4 weeks prior to screening).
Women who are pregnant or lactating.
Known allergy or sensitivity to ANAVEX2-73 or any of its components.
Suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) of type 4 or type 5, or any suicidal behavior, in the past 6 months. Type 4 indicates active suicidal ideation with some intent to act, without a specific plan. Type 5 indicates active suicidal ideation with a specific plan and intent.
Use of centrally acting anticholinergic drugs during the 4 weeks before randomization.
Medications used for overactive bladder will be allowed provided that the regimen has been stable 4 weeks prior to randomization.
Treatment with any dopamine receptor blocking medications with the exception of low dose quetiapine (≤50 mg/day). Pimavanserin (≤34 mg/day) will be allowed.
History of neurosurgical intervention (e.g., deep brain stimulation) for PD.
Unpredictable motor fluctuations that would interfere with administering cognitive assessments in the ON state.